Stock Market News
Indivior sues generic rivals over new Suboxone patent
Indivior has reacted to losing a recent court case by suing companies who are developing generic versions of its opioid addiction treatment .
The Slough-based company's US arm has filed patent lawsuits against generic drugmakers Dr Reddy's, Actavis, Par, Alvogen and Teva for infringing new US patent number 9,931,305, known as the '305 patent, relating to their respective proposed generic versions of its Suboxone film.
The '305 patent, which was issued on 3 April and has been submitted for listing in the FDA's Orange Book, claims film compositions having a substantially uniform distribution of the active drug.
Indivior's lawsuits allege that the generic companies infringe the patent and comes on the back of other patent infringement litigation over its earlier issued patents covering Suboxone with the same companies.
Shaun Thaxter, chief executive of Indivior, said: "The '305 patent, along with the other new Orange Book patents that we secured (the '454 and '221 patents), demonstrates our commitment to innovate and generate new intellectual property for the Suboxone Film. As a follow-on to our '514 patent, we believe this new patent is strong and we are asserting it to protect our intellectual property rights."
Last month, Indivior warned of a potential "rapid and material loss" of sales from its main revenue-generating product after the US District Court of Delaware found Alvogen's generic challenger of Suboxone did not infringe on three of Indivior's US patents.
Indivior's main line of defence in appealing against Alvogen was thought by analysts to be the assertion of the two recently listed Orange Book patents, '454, '221, and the '305.
The Slough-based company's US arm has filed patent lawsuits against generic drugmakers Dr Reddy's, Actavis, Par, Alvogen and Teva for infringing new US patent number 9,931,305, known as the '305 patent, relating to their respective proposed generic versions of its Suboxone film.
The '305 patent, which was issued on 3 April and has been submitted for listing in the FDA's Orange Book, claims film compositions having a substantially uniform distribution of the active drug.
Indivior's lawsuits allege that the generic companies infringe the patent and comes on the back of other patent infringement litigation over its earlier issued patents covering Suboxone with the same companies.
Shaun Thaxter, chief executive of Indivior, said: "The '305 patent, along with the other new Orange Book patents that we secured (the '454 and '221 patents), demonstrates our commitment to innovate and generate new intellectual property for the Suboxone Film. As a follow-on to our '514 patent, we believe this new patent is strong and we are asserting it to protect our intellectual property rights."
Last month, Indivior warned of a potential "rapid and material loss" of sales from its main revenue-generating product after the US District Court of Delaware found Alvogen's generic challenger of Suboxone did not infringe on three of Indivior's US patents.
Indivior's main line of defence in appealing against Alvogen was thought by analysts to be the assertion of the two recently listed Orange Book patents, '454, '221, and the '305.
Related share prices |
---|
Indivior (INDV) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price